Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2021 Filed Nov 1, 2021 20:36 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $525.18 | $52,518.00 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:36 UTC |
Seth AlpnaDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000395 · edgar.xml · derivative · entry 6 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F2 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/2021) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:36 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000395 · edgar.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust #2 Disclosed balance after: 1,330 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust #1 Disclosed balance after: 1,330 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,290 Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:30 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 822 | $529.04 | $434,870.88 |
DisclosureSEC source: 0000914190-21-000374 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $91.78 | $0.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · derivative · entry 7 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $87.39 | $0.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · derivative · entry 6 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 500 | $511.45 | $255,725.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 5 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 4,600 | $510.23 | $2,347,052.48 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 4 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,612 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.98 to $510.597, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 2,900 | $509.33 | $1,477,045.69 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 3 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $508.978 to $509.769, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionCommon Stock | 4,000 | $91.78 | $367,120.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionCommon Stock | 4,000 | $87.39 | $349,560.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 73,492 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,450 Underlying: Common Stock · 73,492 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 42,005 | $510.78 | $21,455,313.90 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,601 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 73,492 | $108.49 | $7,973,147.08 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 7 | $509.17 | $3,564.19 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 9,993 | $507.22 | $5,068,600.49 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,862 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.00 to $507.915, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 6,871 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,503 Underlying: Common Stock · 6,871 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 1,576 | $510.82 | $805,053.58 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.245 to $511.16, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 5,295 | $509.67 | $2,698,710.59 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,196 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.23 to $510.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 6,871 | $125.05 | $859,218.55 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:49 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 1,538 | $503.07 | $773,727.66 |
DisclosureSEC source: 0000914190-21-000322 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.941 to $503.315, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,374 Underlying: Common Stock · 5,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 3,108 | $506.12 | $1,573,010.70 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.92 to $506.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 1,569 | $505.26 | $792,754.82 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,728 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.63 to $505.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 323 | $503.24 | $162,545.97 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,297 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.06 to $503.43, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 5,000 | $125.05 | $625,250.00 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · derivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 4,000 | $481.52 | $1,926,064.80 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 4,000 | $70.35 | $281,400.00 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (right to buy) · Derivative | 4,000 | $0.00 Strike: $87.39 | $0.00 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · derivative · entry 8 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 100 | $487.88 | $48,788.23 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 7 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.87 to $487.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 800 | $487.10 | $389,682.16 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 6 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,712 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.84 to $487.52, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 1,600 | $486.25 | $778,004.16 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,512 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.59 to $486.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 600 | $485.03 | $291,015.24 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,112 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.52 to $485.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 601 | $483.60 | $290,643.18 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.01 to $483.86, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 299 | $481.77 | $144,050.43 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.41 to $482.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:42 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 4,000 | $87.39 | $349,560.00 |
DisclosureSEC source: 0000914190-21-000306 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,704 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,538 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,538 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 600 | $475.05 | $285,032.16 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $474.79 to 475.5250, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 1,838 | $474.12 | $871,426.68 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $473.6350 to $474.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 1,100 | $473.08 | $520,390.53 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,058 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $472.50 to $473.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 3,538 | $106.59 | $377,115.42 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.